https://www.pharmaradar360.com/article/drug-label-update-acetaminophen-extra-strength-cd3f3091fa2d9e7ePharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Acetaminophen Extra Strengthhttps://www.pharmaradar360.com/article/drug-label-update-allergy-relief-d593cd0779dcd03aPharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Allergy Reliefhttps://www.pharmaradar360.com/article/data-is-the-new-commodity-while-the-surgical-robot-is-the-true-enabler-of-the-ne-de8fe4279f1f9ec7Pharma Surgeen2026-07-14T16:23:06.000ZData is the New Commodity, While the Surgical Robot is the True Enabler of the New Economyhttps://www.pharmaradar360.com/article/the-unapproved-but-very-online-weight-loss-drug-3df017d2ac34f893Pharma Surgeen2026-07-14T16:00:00.000ZThe unapproved but very online weight-loss drughttps://www.pharmaradar360.com/article/the-product-that-s-helping-my-blowout-survive-a-new-york-summer-ae9f2471b8bf6676Pharma Surgeen2026-07-14T15:58:18.000ZThe Product That’s Helping My Blowout Survive a New York Summerhttps://www.pharmaradar360.com/article/lumacina-appoints-gary-bird-as-ceo-to-accelerate-growth-and-expand-global-steril-51516cd316dcb7b4Pharma Surgeen2026-07-14T15:47:00.000ZLumaCina Appoints Gary Bird as CEO to Accelerate Growth and Expand Global Sterile Injectables Portfoliohttps://www.pharmaradar360.com/article/fda-finalises-psychedelic-clinical-trial-guidance-c4d6473a3a2fc318Pharma Surgeen2026-07-14T15:43:39.000ZFDA finalises psychedelic clinical trial guidancehttps://www.pharmaradar360.com/article/ministerial-group-for-digital-inclusion-terms-of-reference-64906e0769be48c1Pharma Surgeen2026-07-14T15:43:35.000ZMinisterial Group for Digital Inclusion: terms of referencehttps://www.pharmaradar360.com/article/ministerial-group-for-digital-inclusion-meeting-summaries-b5eb71c24a4b63a9Pharma Surgeen2026-07-14T15:43:31.000ZMinisterial Group for Digital Inclusion: meeting summarieshttps://www.pharmaradar360.com/article/the-u-s-just-approved-a-giant-space-mirror-to-test-sunlight-on-demand-low-earth-9ca5ffd8068e7672Pharma Surgeen2026-07-14T15:38:23.000ZThe U.S. just approved a giant space mirror to test ‘sunlight on demand.’ Low Earth orbit is getting weirdhttps://www.pharmaradar360.com/article/biotech-s-recovery-isn-t-a-head-fake-these-3-stocks-could-lead-the-next-leg-up-8e1beca420654419Pharma Surgeen2026-07-14T15:34:23.000ZBiotech's recovery isn't a 'head fake.' These 3 stocks could lead the next leg uphttps://www.pharmaradar360.com/article/south-korea-s-bio-pharmaceutical-exports-reach-record-4-5-billion-06bd9c6946758cd3Pharma Surgeen2026-07-14T15:32:58.000ZSouth Korea's Bio-Pharmaceutical Exports Reach Record $4.5 Billionhttps://www.pharmaradar360.com/article/new-biotech-avere-plots-listing-via-nextcure-merger-ee80ae17d1699cd8Pharma Surgeen2026-07-14T15:32:51.000ZNew biotech Avere plots listing via NextCure mergerhttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-discloses-transactions-with-avere-therapeutics-eba479018ee4f4d6Pharma Surgeen2026-07-14T15:26:44.000ZHansoh Pharmaceutical Discloses Transactions With Avere Therapeuticshttps://www.pharmaradar360.com/article/notifications-on-data-integrity-8f0694aefbbd1a22Pharma Surgeen2026-07-14T15:20:41.000ZNotifications on Data Integrityhttps://www.pharmaradar360.com/article/the-operational-cost-of-we-ll-add-that-later-7c5644d5f37e6186Pharma Surgeen2026-07-14T15:12:34.000ZThe Operational Cost of “We’ll Add That Later”https://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-biblioteca-publica-7d7618c79a71d883Pharma Surgeen2026-07-14T15:11:19.000ZVacaciones de Invierno en la Biblioteca Públicahttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-teatro-unlp-c6a9638039d74534Pharma Surgeen2026-07-14T15:08:45.000ZVacaciones de Invierno en el Teatro UNLPhttps://www.pharmaradar360.com/article/dhsc-equality-information-106367862a1bd170Pharma Surgeen2026-07-14T15:07:31.000ZDHSC equality informationhttps://www.pharmaradar360.com/article/ems-investe-no-mercado-fitoterapico-parainsonia-com-a-marca-sominex-e-lanca-camp-551c8cc2ee56110ePharma Surgeen2026-07-14T15:04:52.000ZEMS investe no mercado fitoterápico parainsônia com a marca Sominex e lança campanha exclusiva com ações inéditas na TVhttps://www.pharmaradar360.com/article/5-early-career-faculty-win-2026-hettleman-prizes-987490657e3c0d68Pharma Surgeen2026-07-14T15:04:23.000Z5 early-career faculty win 2026 Hettleman Prizeshttps://www.pharmaradar360.com/article/dhsc-equality-information-2025-8be8df30649a6a71Pharma Surgeen2026-07-14T15:03:59.000ZDHSC equality information: 2025https://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-centro-de-arte-unlp-5d2512de6e8ce047Pharma Surgeen2026-07-14T15:00:14.000ZVacaciones de Invierno en el Centro de Arte UNLPhttps://www.pharmaradar360.com/article/dr-s-leigh-verbois-named-chief-executive-officer-of-rx-360-d16984b7fc10e300Pharma Surgeen2026-07-14T15:00:00.000ZDr. S. Leigh Verbois Named Chief Executive Officer of Rx-360https://www.pharmaradar360.com/article/pharmaceutical-waste-outreach-program-6075948888daa031Pharma Surgeen2026-07-14T14:59:29.000ZPharmaceutical Waste Outreach Programhttps://www.pharmaradar360.com/article/cannara-biotech-lands-a-first-long-term-export-supply-deal-393da85c73c0e877Pharma Surgeen2026-07-14T14:58:25.000ZCannara Biotech Lands A First Long-Term Export Supply Dealhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-museo-de-quimica-y-farmacia-1c2aec5cd6fc162cPharma Surgeen2026-07-14T14:57:56.000ZVacaciones de Invierno en el Museo de Química y Farmaciahttps://www.pharmaradar360.com/article/uk-research-and-innovation-publishes-2025-to-2026-annual-report-fc44c978c0417be6Pharma Surgeen2026-07-14T14:57:54.000ZUK Research and Innovation publishes 2025 to 2026 annual reporthttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-unlp-70244ab8c5384bacPharma Surgeen2026-07-14T14:55:57.000ZVacaciones de Invierno en la UNLPhttps://www.pharmaradar360.com/article/biotech-companies-tout-benefits-of-ai-assisted-drug-development-3e0d21e6183cafd9Pharma Surgeen2026-07-14T14:55:35.000ZBiotech companies tout benefits of AI-assisted drug developmenthttps://www.pharmaradar360.com/article/seatbelts-still-essential-but-nearly-9-in-10-pregnant-people-didn-t-achieve-reco-e1dc01e66b779ddbPharma Surgeen2026-07-14T14:55:00.000ZSeatbelts still essential, but nearly 9 in 10 pregnant people didn’t achieve recommended seatbelt placement: studyhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-planetario-unlp-442f8cfb32e11374Pharma Surgeen2026-07-14T14:54:55.000ZVacaciones de Invierno en el Planetario UNLPhttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-la-facultad-de-cs-astronomicas-y-geofisicas-2bdb44ce8a3ae088Pharma Surgeen2026-07-14T14:52:51.000ZVacaciones de Invierno en la Facultad de Cs. Astronómicas y Geofísicashttps://www.pharmaradar360.com/article/his-majesty-the-king-officially-opens-the-uk-space-and-defence-gateway-8cd24c047b8c8f82Pharma Surgeen2026-07-14T14:52:50.000ZHis Majesty the King officially opens the UK Space and Defence Gatewayhttps://www.pharmaradar360.com/article/after-k-rustom-fda-suspends-licences-of-mumbai-s-iconic-shalimar-noor-mohammadi-8a6f2c769c41afa3Pharma Surgeen2026-07-14T14:52:13.000ZAfter K Rustom, FDA suspends licences of Mumbai’s iconic Shalimar, Noor Mohammadi over alleged hygiene lapseshttps://www.pharmaradar360.com/article/ems-e-top-of-mind-pelo-quinto-ano-consecutivo-aponta-datafolha-fb80ecf6ad5f07cePharma Surgeen2026-07-14T14:52:10.000ZEMS é Top of Mind pelo quinto ano consecutivo, aponta Datafolhahttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-mundo-nuevo-dcd0d754f1830b25Pharma Surgeen2026-07-14T14:50:32.000ZVacaciones de Invierno en Mundo Nuevohttps://www.pharmaradar360.com/article/vacaciones-de-invierno-en-el-museo-de-la-plata-0813d15a24828925Pharma Surgeen2026-07-14T14:47:06.000ZVacaciones de Invierno en el Museo de La Platahttps://www.pharmaradar360.com/article/akero-team-backed-by-fairmount-launches-new-immunology-company-ff41db2f427fe540Pharma Surgeen2026-07-14T14:46:49.000ZAkero team, backed by Fairmount, launches new immunology companyhttps://www.pharmaradar360.com/article/marco-historico-para-o-pais-afirma-alexandre-padilha-sobre-nova-fabrica-da-ems-ef90d5276646d8dePharma Surgeen2026-07-14T14:34:47.000Z“Marco histórico para o país”, afirma Alexandre Padilha sobre nova fábrica da EMShttps://www.pharmaradar360.com/article/cellares-recent-automated-cell-therapy-wins-have-opened-the-biotech-floodgates-dfeb49278fd2cf01Pharma Surgeen2026-07-14T14:26:00.000ZCellares' recent automated cell therapy wins have 'opened the biotech floodgates'https://www.pharmaradar360.com/article/pharma-m-a-roundup-astrazeneca-enters-license-deal-with-dizal-pharmaceutical-cha-97c4be2ea558fc39Pharma Surgeen2026-07-14T14:22:56.000ZPharma M&A Roundup: AstraZeneca Enters License Deal with Dizal Pharmaceutical, Chai Discovery Enters Collaboration with Novartis, Innovent Biologics Enters License Agreement with Spero Therapeuticshttps://www.pharmaradar360.com/article/russian-billionaire-wins-fight-to-boot-manager-of-biotech-fund-e1d9752acaf9ed91Pharma Surgeen2026-07-14T14:15:09.000ZRussian billionaire wins fight to boot manager of biotech fundhttps://www.pharmaradar360.com/article/nihr-sphr-fellowships-in-public-health-research-2026-390fc89853010f9fPharma Surgeen2026-07-14T14:14:20.000ZNIHR SPHR fellowships in public health research 2026https://www.pharmaradar360.com/article/biotech-visionary-john-f-crowley-to-keynote-emily-whitehead-foundation-s-2026-be-89d22fbe02d868b7Pharma Surgeen2026-07-14T14:10:00.000ZBiotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphiahttps://www.pharmaradar360.com/article/transparency-data-medicines-and-healthcare-products-regulatory-agency-privacy-no-850c32c5410b0cb8Pharma Surgeen2026-07-14T14:07:17.000ZTransparency data: Medicines and Healthcare products Regulatory Agency Privacy Noticehttps://www.pharmaradar360.com/article/medicaid-waiver-tracker-approved-and-pending-section-1115-waivers-by-state-f0d871bdab45e9c4Pharma Surgeen2026-07-14T14:06:14.000ZMedicaid Waiver Tracker: Approved and Pending Section 1115 Waivers by Statehttps://www.pharmaradar360.com/article/recognized-educator-karenbeth-bohan-retires-from-sopps-f662e98f341203ddPharma Surgeen2026-07-14T14:00:54.000ZRecognized educator KarenBeth Bohan retires from SOPPShttps://www.pharmaradar360.com/article/clinical-success-for-cns-mabs-depends-on-more-than-mechanisms-of-action-alone-1e1b5a00e219f60fPharma Surgeen2026-07-14T14:00:34.000ZClinical success for CNS mAbs depends on more than mechanisms of action alonehttps://www.pharmaradar360.com/article/madden-nfl-27-arcade-edition-brings-gridiron-action-to-apple-arcade-on-august-6-030bac555e2fd462Pharma Surgeen2026-07-14T13:59:25.000ZMadden NFL 27 Arcade Edition brings gridiron action to Apple Arcade on August 6https://www.pharmaradar360.com/article/la-unlp-acordo-mejorar-la-frecuencia-del-talp-y-beneficia-a-miles-de-estudiantes-4f1d8fde652f5233Pharma Surgeen2026-07-14T13:57:59.000ZLa UNLP acordó mejorar la frecuencia del TALP y beneficia a miles de estudiantes del conurbanohttps://www.pharmaradar360.com/article/glasgow-fair-public-holiday-reminder-0f4ff97fdfdca836Pharma Surgeen2026-07-14T13:52:50.000ZGlasgow Fair public holiday reminderhttps://www.pharmaradar360.com/article/biotech-funding-gap-widens-despite-rebound-in-vc-investment-b1559510585c639dPharma Surgeen2026-07-14T13:41:15.000ZBiotech funding gap widens despite rebound in VC investmenthttps://www.pharmaradar360.com/article/biogen-plans-phase-3-trial-for-alzheimer-s-drug-diranersen-by-investing-com-4f99c61db4d6a5d9Pharma Surgeen2026-07-14T13:38:36.000ZBiogen plans phase 3 trial for Alzheimer’s drug diranersen By Investing.comhttps://www.pharmaradar360.com/article/ipos-juice-biotech-real-estate-if-only-a-little-but-vacancy-still-climbs-and-lea-0a22cf5df7824679Pharma Surgeen2026-07-14T13:38:00.000ZIPOs juice biotech real estate (if only a little), but vacancy still climbs and lease rates tumblehttps://www.pharmaradar360.com/article/tuberculosis-in-england-national-quarterly-report-q2-2026-7c808e6c9251c844Pharma Surgeen2026-07-14T13:32:30.000ZTuberculosis in England national quarterly report: Q2 2026https://www.pharmaradar360.com/article/pharmaceutical-manufacturing-validation-batch-integrity-and-what-a-cyber-inciden-d902f3316c9ecc8ePharma Surgeen2026-07-14T13:30:00.000ZPharmaceutical manufacturing: Validation, batch integrity, and what a cyber incident actually costshttps://www.pharmaradar360.com/article/peticion-para-reconocer-el-ecocidio-crimen-de-lesa-humanidad-bf9f00b9b3c5bff8Pharma Surgeen2026-07-14T13:29:20.000ZPetición para reconocer el Ecocidio Crimen de Lesa Humanidadhttps://www.pharmaradar360.com/article/eating-chili-peppers-may-raise-the-risk-of-one-deadly-cancer-183ee83a03a94a61Pharma Surgeen2026-07-14T13:27:21.000ZEating chili peppers may raise the risk of one deadly cancerhttps://www.pharmaradar360.com/article/shortly-after-bankruptcy-io-biotech-founder-takes-on-new-top-position-761179ae01b38ee3Pharma Surgeen2026-07-14T13:26:24.000ZShortly after bankruptcy: IO Biotech founder takes on new top positionhttps://www.pharmaradar360.com/article/germany-passes-bill-despite-criticism-from-pharmaceutical-companies-381e48fe3471214bPharma Surgeen2026-07-14T13:21:00.000ZGermany passes bill despite criticism from pharmaceutical companieshttps://www.pharmaradar360.com/article/novel-vaccine-framework-illustrates-promise-for-oral-cancer-vaccines-951bffa5c2516866Pharma Surgeen2026-07-14T13:19:28.000ZNovel vaccine framework illustrates promise for oral cancer vaccineshttps://www.pharmaradar360.com/article/summit-sells-failed-antibiotic-to-openai-backed-startup-in-105m-deal-9273ccc176c89b05Pharma Surgeen2026-07-14T13:17:45.000ZSummit sells failed antibiotic to OpenAI-backed startup in $105M dealhttps://www.pharmaradar360.com/article/biogen-data-highlight-promise-questions-surrounding-tau-targeting-alzheimer-s-dr-32078bd05605f6b5Pharma Surgeen2026-07-14T13:17:45.000ZBiogen data highlight promise, questions surrounding tau-targeting Alzheimer’s drugshttps://www.pharmaradar360.com/article/trusted-cheminformatics-zero-integration-headaches-ml-in-python-with-chemaxon-fbeb10a2862dd3e4Pharma Surgeen2026-07-14T13:04:38.000ZTrusted Cheminformatics, Zero Integration Headaches: ML in Python with Chemaxonhttps://www.pharmaradar360.com/article/988-enters-its-fourth-year-as-demand-grows-and-the-mental-health-and-substance-u-7e8bb9493d628ddePharma Surgeen2026-07-14T13:00:00.000Z988 Enters Its Fourth Year as Demand Grows and the Mental Health and Substance Use Landscape Shiftshttps://www.pharmaradar360.com/article/3-things-to-know-about-substance-use-and-suicide-mortality-e8f57c131d2011dbPharma Surgeen2026-07-14T13:00:00.000Z3 Things to Know About Substance Use and Suicide Mortalityhttps://www.pharmaradar360.com/article/danish-biotech-sells-future-royalties-to-bring-its-first-product-to-market-d417c94ec89d2298Pharma Surgeen2026-07-14T12:59:00.000ZDanish biotech sells future royalties to bring its first product to markethttps://www.pharmaradar360.com/article/adneuris-therapeutics-grants-exclusive-license-to-zhejiang-conba-pharmaceutical-df5184412e1ae8f8Pharma Surgeen2026-07-14T12:52:53.000ZAdneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater Chinahttps://www.pharmaradar360.com/article/the-new-era-of-pharma-distribution-balancing-precision-and-scale-11eec0ed16e6e3fcPharma Surgeen2026-07-14T12:39:35.000ZThe New Era of Pharma Distribution: Balancing Precision and Scalehttps://www.pharmaradar360.com/article/surgical-infections-cost-hospitals-billions-one-under-the-radar-biotech-player-m-fc320956fc36df3cPharma Surgeen2026-07-14T12:30:05.000ZSurgical Infections Cost Hospitals Billions. One Under-the-Radar Biotech Player Might be About to Change Thathttps://www.pharmaradar360.com/article/steering-the-formation-of-engineered-tissue-by-sound-waves-6c6f0718283a8903Pharma Surgeen2026-07-14T12:28:52.000ZSteering the Formation of Engineered Tissue by Sound Waveshttps://www.pharmaradar360.com/article/menb-vaccination-programme-eligible-residential-further-education-settings-ea1c926b97083608Pharma Surgeen2026-07-14T12:22:55.000ZMenB vaccination programme: eligible residential further education settingshttps://www.pharmaradar360.com/article/la-aemps-informa-de-que-la-ue-amplia-a-81-el-numero-de-alergenos-de-fragancias-q-324a51990a9aced2Pharma Surgeen2026-07-14T12:19:42.000ZLa AEMPS informa de que la UE amplía a 81 el número de alérgenos de fragancias que deberán etiquetarse en el listado de ingredientes de cosméticoshttps://www.pharmaradar360.com/article/kemri-delivers-on-ebola-preparedness-pledge-with-critical-ipc-supplies-589164f5884aaa2fPharma Surgeen2026-07-14T12:17:51.000ZKEMRI Delivers on Ebola Preparedness Pledge with Critical IPC Supplieshttps://www.pharmaradar360.com/article/can-fite-secures-australian-patent-allowance-supporting-namodenoson-development-9cbb740e30a2b80ePharma Surgeen2026-07-14T12:14:29.000ZCan-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancerhttps://www.pharmaradar360.com/article/ai-ml-in-practice-machine-learning-prediction-of-chromatographic-retention-times-85adbf7f79585669Pharma Surgeen2026-07-14T12:11:14.000ZAI/ML in Practice: Machine-learning Prediction of Chromatographic Retention Times for Small Molecules in Pharmaceutical Applicationshttps://www.pharmaradar360.com/article/campus-less-accessible-due-to-resurfacing-of-abram-van-rijckevorselweg-3cf121b31486ff02Pharma Surgeen2026-07-14T12:07:55.000ZCampus less accessible due to resurfacing of Abram van Rijckevorselweghttps://www.pharmaradar360.com/article/progress-in-food-fortification-highlighted-as-experts-call-for-stronger-action-a-a00c3e3659957dbcPharma Surgeen2026-07-14T12:07:42.000ZProgress in Food Fortification Highlighted as Experts Call for Stronger Action Across Eastern and Southern Africahttps://www.pharmaradar360.com/article/compass-has-two-positive-phase-3-trials-the-fda-has-final-guidance-so-why-does-p-51e04535f6c64361Pharma Surgeen2026-07-14T12:05:40.000ZCompass Has Two Positive Phase 3 Trials. The FDA Has Final Guidance. So Why Does Psilocybin Still Feel Like a Gamble?https://www.pharmaradar360.com/article/skinmedica-deepens-commitment-to-regenerative-science-with-continued-investment-a98b88dc5dbb7778Pharma Surgeen2026-07-14T12:05:00.000ZSkinMedica® Deepens Commitment to Regenerative Science with Continued Investment in Research and Developmenthttps://www.pharmaradar360.com/article/gemelos-digitales-la-revolucion-tecnologica-que-obliga-a-debatir-privacidad-dere-a849959c910684e5Pharma Surgeen2026-07-14T12:02:18.000ZGemelos digitales: la revolución tecnológica que obliga a debatir privacidad, derechos y algoritmoshttps://www.pharmaradar360.com/article/dolphins-dropping-in-to-the-sea-of-japan-e47fdbf7f129b122Pharma Surgeen2026-07-14T12:00:00.000ZDolphins dropping in to the Sea of Japanhttps://www.pharmaradar360.com/article/mainshock-locations-shape-earthquake-size-distributions-59f30b10df8e1f21Pharma Surgeen2026-07-14T12:00:00.000ZMainshock locations shape earthquake size distributionshttps://www.pharmaradar360.com/article/small-differences-in-classroom-ranking-can-shape-secondary-school-advice-fe130732d891418bPharma Surgeen2026-07-14T12:00:00.000ZSmall differences in classroom ranking can shape secondary school advicehttps://www.pharmaradar360.com/article/element-biosciences-prevails-in-german-patent-case-against-illumina-b3b817f2da7d1d45Pharma Surgeen2026-07-14T12:00:00.000ZElement Biosciences Prevails in German Patent Case Against Illuminahttps://www.pharmaradar360.com/article/end-to-end-traceability-connecting-source-systems-and-tmf-7b13c90b49b3989ePharma Surgeen2026-07-14T12:00:00.000ZEnd-to-End Traceability: Connecting Source, Systems, and TMFhttps://www.pharmaradar360.com/article/investigadores-de-la-unlp-y-del-conicet-se-preparan-para-la-nueva-era-de-alta-lu-526228d8bfd86729Pharma Surgeen2026-07-14T11:58:25.000ZInvestigadores de la UNLP y del CONICET se preparan para la nueva era de “alta luminosidad” de la física de partículashttps://www.pharmaradar360.com/article/emergenza-ondate-di-calore-attivo-cold-spot-al-policlinico-di-milano-contro-i-di-3f7f644104fc411cPharma Surgeen2026-07-14T11:56:00.000ZEmergenza ondate di calore: attivo Cold Spot al Policlinico di Milano contro i disturbi da caldo intensohttps://www.pharmaradar360.com/article/germany-pharmaceutical-grade-polyethylene-glycol-market-analysis-forecast-size-t-ac8c97c2759e06cdPharma Surgeen2026-07-14T11:52:07.000ZGermany Pharmaceutical Grade Polyethylene Glycol - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/recent-cancer-trial-failures-and-setbacks-a-quick-look-42d51efe755f5578Pharma Surgeen2026-07-14T11:46:41.000ZRecent Cancer Trial Failures and Setbacks: A Quick Lookhttps://www.pharmaradar360.com/article/vota-l-archivio-storico-del-policlinico-di-milano-fra-i-luoghi-del-cuore-fai-805384554a64d0efPharma Surgeen2026-07-14T11:38:00.000ZVota l’Archivio Storico del Policlinico di Milano fra "I Luoghi del cuore FAI"https://www.pharmaradar360.com/article/pharma-facilities-begin-gateway-rollout-with-up-to-4x-faster-screening-c1caff65e77b66a1Pharma Surgeen2026-07-14T11:30:00.000ZPharma Facilities Begin Gateway Rollout With Up to 4x Faster Screeninghttps://www.pharmaradar360.com/article/preterm-birth-impacts-early-educational-achievements-face31a4a8abacb3Pharma Surgeen2026-07-14T11:20:17.000ZPreterm birth impacts early educational achievementshttps://www.pharmaradar360.com/article/die-kunst-des-im-wandel-seins-2077620d94aac233Pharma Surgeen2026-07-14T11:17:01.000ZDie Kunst des „Im Wandel-Seins“https://www.pharmaradar360.com/article/agenus-stock-doubles-as-biotech-narrows-phase-3-bet-ff97219e0d6ea283Pharma Surgeen2026-07-14T11:17:00.000ZAgenus stock doubles as biotech narrows Phase 3 bethttps://www.pharmaradar360.com/article/ai-biopharma-biossil-plans-to-advance-experimental-c-diff-drug-a822bb3813fed51aPharma Surgeen2026-07-14T11:07:14.000ZAI Biopharma Biossil Plans to Advance Experimental C. diff Drughttps://www.pharmaradar360.com/article/hepatitis-e-has-no-approved-treatments-as-atea-begins-human-trial-7ebed53cc2c67ad0Pharma Surgeen2026-07-14T11:00:00.000ZHepatitis E Has No Approved Treatments as Atea Begins Human Trialhttps://www.pharmaradar360.com/article/can-fite-s-namodenoson-in-phase-3-liver-cancer-study-pancreatic-trial-planned-3bcdb8879c5bea92Pharma Surgeen2026-07-14T11:00:00.000ZCan-Fite's Namodenoson in Phase 3 liver cancer study; pancreatic trial plannedhttps://www.pharmaradar360.com/article/summit-therapeutics-signs-agreement-to-sell-phase-iii-asset-ridinilazole-to-bios-babe1e65b5e9fe5dPharma Surgeen2026-07-14T11:00:00.000ZSummit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.https://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-d752ae113c772fa1Pharma Surgeen2026-07-14T10:59:54.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/catching-the-drift-how-wildfire-smoke-plumes-may-increase-cancer-risk-db8e7b2f5dceea70Pharma Surgeen2026-07-14T10:57:34.000ZCatching the Drift: How Wildfire Smoke Plumes May Increase Cancer Riskhttps://www.pharmaradar360.com/article/new-map-shows-how-pharmaceuticals-support-jobs-health-and-growth-across-every-uk-bd057dc21a414301Pharma Surgeen2026-07-14T10:55:59.000ZNew map shows how pharmaceuticals support jobs, health and growth across every UK nationhttps://www.pharmaradar360.com/article/european-biotech-chases-record-vc-funding-a3776ba34e3dfb6cPharma Surgeen2026-07-14T10:53:36.000ZEuropean biotech chases record VC fundinghttps://www.pharmaradar360.com/article/fortrea-mdd-advancing-diagnostic-imaging-trials-through-global-experience-e9d52a44cf6e4246Pharma Surgeen2026-07-14T10:50:06.000ZFortrea MDD: Advancing diagnostic imaging trials through global experiencehttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-mycenax-biotech-inc-tpex-4726-47862dba646287b8Pharma Surgeen2026-07-14T10:43:14.000ZEnterprise value to EBITDA forward of Mycenax Biotech Inc. – TPEX:4726https://www.pharmaradar360.com/article/unpaid-carers-action-plan-recognise-refer-reach-9e6352a24c35b04aPharma Surgeen2026-07-14T10:42:29.000ZUnpaid carers action plan: recognise, refer, reachhttps://www.pharmaradar360.com/article/biotech-infrastructure-review-where-investment-is-flowing-84227229c8d8aad6Pharma Surgeen2026-07-14T10:32:14.000ZBiotech infrastructure review: where investment is flowinghttps://www.pharmaradar360.com/article/cathay-biotech-and-unit-file-trade-secret-infringement-lawsuit-8e062eb4314528afPharma Surgeen2026-07-14T10:32:04.000ZCathay Biotech And Unit File Trade Secret Infringement Lawsuithttps://www.pharmaradar360.com/article/atrium-s-first-prkag2-trial-to-evaluate-treatment-for-disease-cause-da250a8a72b76ed6Pharma Surgeen2026-07-14T10:30:00.000ZAtrium's First PRKAG2 Trial to Evaluate Treatment for Disease Causehttps://www.pharmaradar360.com/article/hansoh-pharmaceutical-pharma-announces-license-collaboration-and-strategic-inves-77d6f1deca86eb20Pharma Surgeen2026-07-14T10:20:05.000ZHansoh Pharmaceutical : PHARMA ANNOUNCES LICENSE COLLABORATION AND STRATEGIC INVESTMENT WITH AVERE FOR ORAL IL‑23 ASSET HS‑20118https://www.pharmaradar360.com/article/shampoo-chemicals-in-your-milk-2-crore-adulteration-racket-exposed-in-maharashtr-8c2b6e5c75ba4a29Pharma Surgeen2026-07-14T10:13:01.000ZShampoo, chemicals in your milk? ₹2 crore adulteration racket exposed in Maharashtrahttps://www.pharmaradar360.com/article/sabto-reports-and-guidance-documents-a9d6712ad78069caPharma Surgeen2026-07-14T10:12:20.000ZSaBTO reports and guidance documentshttps://www.pharmaradar360.com/article/sabto-annual-report-2024-to-2025-6664dca759a80d04Pharma Surgeen2026-07-14T10:12:14.000ZSaBTO annual report 2024 to 2025https://www.pharmaradar360.com/article/centogene-takes-ownership-in-pearl-medical-analysis-lab-in-abu-dhabi-069efc0d7654e28fPharma Surgeen2026-07-14T10:09:41.000ZCENTOGENE takes ownership in Pearl Medical Analysis Lab in Abu Dhabihttps://www.pharmaradar360.com/article/effect-edesa-biotech-inc-sec-filing-1b6bb1a899d47164Pharma Surgeen2026-07-14T10:05:42.000Z[EFFECT] Edesa Biotech, Inc. SEC Filinghttps://www.pharmaradar360.com/article/swimmer-archie-goodburn-goes-from-graduation-to-the-games-50dd2067a0017dcaPharma Surgeen2026-07-14T10:02:19.000ZSwimmer Archie Goodburn goes from graduation to the Gameshttps://www.pharmaradar360.com/article/northwestern-medicine-performs-first-known-quadruple-organ-transplant-involving-29fff7716c5b0f67Pharma Surgeen2026-07-14T10:00:00.000ZNorthwestern Medicine performs first known quadruple-organ transplant involving retransplanted lungshttps://www.pharmaradar360.com/article/spero-s-1-1b-antibody-deal-targets-two-immune-diseases-a0f7d204e6018177Pharma Surgeen2026-07-14T10:00:00.000ZSpero’s $1.1B antibody deal targets two immune diseaseshttps://www.pharmaradar360.com/article/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-mean-2cb7908e39c94257Pharma Surgeen2026-07-14T10:00:00.000ZDonald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibbhttps://www.pharmaradar360.com/article/after-4-7b-sale-to-novo-nordisk-former-akero-team-announces-new-i-i-company-with-572baff3d3ab062bPharma Surgeen2026-07-14T10:00:00.000ZAfter $4.7B sale to Novo Nordisk, former Akero team announces new I&I company with China drughttps://www.pharmaradar360.com/article/cambridge-biotech-strikes-1-1b-deal-with-chinese-partner-shifts-to-immunology-149b3bddbee9c30bPharma Surgeen2026-07-14T10:00:00.000ZCambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunologyhttps://www.pharmaradar360.com/article/avere-goes-public-via-nextcure-reverse-merger-secures-hansoh-il-23-drug-with-2-3-e467ec2645f08dd7Pharma Surgeen2026-07-14T09:59:33.000ZAvere goes public via NextCure reverse merger, secures Hansoh IL-23 drug with $2.3B dealhttps://www.pharmaradar360.com/article/arbs-green-biotech-innovator-with-key-partnerships-in-cosmetics-and-agriculture-18cd737ba40422ffPharma Surgeen2026-07-14T09:58:27.000ZARBS: Green biotech innovator with key partnerships in cosmetics and agriculturehttps://www.pharmaradar360.com/article/pneumococcal-vaccination-programmes-for-infants-adults-and-individuals-at-increa-8050db2fd0e7d296Pharma Surgeen2026-07-14T09:57:07.000ZPneumococcal vaccination programmes for infants, adults and individuals at increased clinical riskhttps://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-e3e52df111bc10c3Pharma Surgeen2026-07-14T09:57:00.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/popular-weight-loss-drugs-ozempic-and-wegovy-may-slow-biological-aging-e828f2bf095ce12dPharma Surgeen2026-07-14T09:47:41.000ZPopular weight-loss drugs Ozempic and Wegovy may slow biological aginghttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-fd246bfb71da8600Pharma Surgeen2026-07-14T09:47:06.000ZElevara Medicines appoints biotech veteran as CEOhttps://www.pharmaradar360.com/article/novartis-and-chai-discovery-collaborate-on-antibody-identification-f57c9644a1610023Pharma Surgeen2026-07-14T09:45:23.000ZNovartis and Chai Discovery collaborate on antibody identificationhttps://www.pharmaradar360.com/article/annexon-perfect-complement-to-a-speculative-biotech-portfolio-nasdaq-annx-658c587052e9a219Pharma Surgeen2026-07-14T09:43:52.000ZAnnexon: Perfect Complement To A Speculative Biotech Portfolio (NASDAQ:ANNX)https://www.pharmaradar360.com/article/travellers-reminded-to-take-precautions-to-avoid-infections-abroad-this-summer-4601fa70feb533c8Pharma Surgeen2026-07-14T09:38:09.000ZTravellers reminded to take precautions to avoid infections abroad this summerhttps://www.pharmaradar360.com/article/digital-process-development-for-cell-and-gene-therapy-d8b4e193c258b7c8Pharma Surgeen2026-07-14T09:35:00.000ZDigital process development for cell and gene therapyhttps://www.pharmaradar360.com/article/25-transfers-in-21-years-who-is-tukaram-mundhe-ias-officer-leading-maharashtra-s-17c166fff07b641cPharma Surgeen2026-07-14T09:27:39.000Z25 Transfers in 21 Years: Who is Tukaram Mundhe? IAS Officer Leading Maharashtra’s Food Safety Crackdownhttps://www.pharmaradar360.com/article/germany-approves-healthcare-costs-overhaul-despite-significant-pharma-opposition-392d13fc25f07602Pharma Surgeen2026-07-14T09:22:47.000ZGermany approves healthcare costs overhaul despite significant pharma oppositionhttps://www.pharmaradar360.com/article/donald-trump-s-drug-pricing-deals-are-reshaping-big-pharma-here-s-what-that-mean-a171df846ecb22a9Pharma Surgeen2026-07-14T09:20:18.000ZDonald Trump's Drug-Pricing Deals Are Reshaping Big Pharma -- Here's What That Means for Pfizer, AbbVie, and Bristol Myers Squibbhttps://www.pharmaradar360.com/article/field-safety-notices-6-to-10-july-2026-46da3042a83bf244Pharma Surgeen2026-07-14T09:19:00.000ZField Safety Notices: 6 to 10 July 2026https://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-eb4776f026fe0d4cPharma Surgeen2026-07-14T09:17:26.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/cathie-wood-is-loading-up-on-this-biotech-stock-is-it-a-no-brainer-buy-e65fb14aab7606e5Pharma Surgeen2026-07-14T09:17:00.000ZCathie Wood Is Loading Up on This Biotech Stock. Is It a No-Brainer Buy?https://www.pharmaradar360.com/article/reports-of-cases-of-tb-to-uk-enhanced-tuberculosis-surveillance-systems-2000-to-7bbe0add77b9e3d5Pharma Surgeen2026-07-14T09:14:08.000ZReports of cases of TB to UK enhanced tuberculosis surveillance systems 2000 to 2025https://www.pharmaradar360.com/article/molecular-map-of-liver-disease-could-transform-how-masld-is-diagnosed-and-monito-6db1b03b80ce7287Pharma Surgeen2026-07-14T09:09:42.000ZMolecular map of liver disease could transform how MASLD is diagnosed and monitoredhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-9-august-2026-9b85cffeadf04a35Pharma Surgeen2026-07-14T09:09:22.000ZWeekly all-cause mortality surveillance: week ending 9 August 2026https://www.pharmaradar360.com/article/national-flu-and-covid-19-surveillance-report-week-33-report-data-to-week-32-dat-1333b67e4538d4d8Pharma Surgeen2026-07-14T09:09:13.000ZNational flu and COVID-19 surveillance report, week 33 report: data to week 32 (data up to 9 August 2026)https://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-2-august-2026-9727509b061a9ef9Pharma Surgeen2026-07-14T09:09:03.000ZWeekly all-cause mortality surveillance: week ending 2 August 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-older-adults-vaccination-coverage-in-england-jun-6e405552d2e63be0Pharma Surgeen2026-07-14T09:08:57.000ZRespiratory syncytial virus (RSV) older adults vaccination coverage in England: June 2026https://www.pharmaradar360.com/article/respiratory-syncytial-virus-rsv-maternal-vaccination-coverage-in-england-march-2-30e801b2e4b499e7Pharma Surgeen2026-07-14T09:08:49.000ZRespiratory syncytial virus (RSV) maternal vaccination coverage in England: March 2026https://www.pharmaradar360.com/article/138-doktorurkunden-vier-stiftungspreise-und-ein-nobelpreistrager-9809bcbb627dffcfPharma Surgeen2026-07-14T09:08:47.000Z138 Doktorurkunden, vier Stiftungspreise und ein Nobelpreisträgerhttps://www.pharmaradar360.com/article/china-resources-pharmaceutical-refreshes-board-with-new-non-executive-director-c73ac853c6b6394dPharma Surgeen2026-07-14T09:06:36.000ZChina Resources Pharmaceutical Refreshes Board With New Non-Executive Directorhttps://www.pharmaradar360.com/article/why-cross-sector-collaboration-in-ai-is-the-key-to-unlocking-new-medicines-23b1a9bf1c6b4888Pharma Surgeen2026-07-14T09:06:35.000ZWhy cross-sector collaboration in AI is the key to unlocking new medicineshttps://www.pharmaradar360.com/article/increase-uptime-with-recommended-parts-inventory-5a17317e9534ef3dPharma Surgeen2026-07-14T09:05:56.000ZIncrease uptime with Recommended Parts Inventoryhttps://www.pharmaradar360.com/article/the-ai-arms-race-in-administrative-health-care-4b9ac3df0d4d8ce9Pharma Surgeen2026-07-14T09:00:00.000ZThe AI Arms Race in Administrative Health Carehttps://www.pharmaradar360.com/article/americans-for-safe-and-effective-medicines-launches-to-protect-patients-from-ill-893b0b035efe4c79Pharma Surgeen2026-07-14T09:00:00.000ZAmericans for Safe and Effective Medicines Launches to Protect Patients from Illegal Mass Compounding, Counterfeit Drugs, and Misleading Marketinghttps://www.pharmaradar360.com/article/acg-metals-rockfire-resources-sunda-energy-cellbxhealth-poolbeg-pharmaceutical-35990f01485a3cf0Pharma Surgeen2026-07-14T08:57:48.000ZACG Metals, Rockfire Resources, Sunda Energy, CelLBxHealth, Poolbeg Pharmaceuticalhttps://www.pharmaradar360.com/article/celltrion-ends-europe-phase-3-for-keytruda-biosimilar-as-regulators-ease-rules-c-c0f4becfabc5316ePharma Surgeen2026-07-14T08:55:00.000ZCelltrion ends Europe phase 3 for Keytruda biosimilar as regulators ease rules - CHOSUNBIZhttps://www.pharmaradar360.com/article/even-though-there-are-world-class-large-hospitals-it-is-difficult-to-secure-glob-feb893f0decbc39fPharma Surgeen2026-07-14T08:51:17.000ZEven though there are world-class large hospitals, it is difficult to secure global competitiveness..https://www.pharmaradar360.com/article/jilin-aodong-pharmaceutical-sees-h1-net-profit-up-50-70-y-y-ada222b91453056ePharma Surgeen2026-07-14T08:47:52.000ZJilin Aodong Pharmaceutical Sees H1 Net Profit Up 50-70% Y/Yhttps://www.pharmaradar360.com/article/regulator-eases-biosimilar-approval-requirements-waiving-some-phase-3-trial-data-788b46d0ac4e12efPharma Surgeen2026-07-14T08:42:32.000ZRegulator eases biosimilar approval requirements, waiving some phase 3 trial datahttps://www.pharmaradar360.com/article/biotech-ushers-in-new-class-of-personal-care-ingredients-fa9607040ddec366Pharma Surgeen2026-07-14T08:42:19.000ZBiotech ushers in new class of personal care ingredientshttps://www.pharmaradar360.com/article/guidance-in-vitro-diagnostic-point-of-care-test-devices-8cf6f19f1fa74a70Pharma Surgeen2026-07-14T08:40:53.000ZGuidance: In vitro diagnostic point-of-care test deviceshttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-ee518c890bb23dffPharma Surgeen2026-07-14T08:40:28.000ZElevara Medicines Appoints Biotech Veteran as CEOhttps://www.pharmaradar360.com/article/new-trial-offers-hope-for-people-with-rare-adrenal-cancer-c6685133e6a6ac55Pharma Surgeen2026-07-14T08:38:03.000ZNew trial offers hope for people with rare adrenal cancerhttps://www.pharmaradar360.com/article/pneumococcal-vaccination-expansion-of-eligibility-to-people-experiencing-homeles-44e10e0781988674Pharma Surgeen2026-07-14T08:30:03.000ZPneumococcal vaccination: expansion of eligibility to people experiencing homelessnesshttps://www.pharmaradar360.com/article/laboratory-confirmed-zika-virus-disease-cases-statistics-ce9ca844e3bbb799Pharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed Zika virus disease cases: statisticshttps://www.pharmaradar360.com/article/laboratory-confirmed-typhoid-and-paratyphoid-cases-statistics-32ed718d28bc48dfPharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed typhoid and paratyphoid cases: statisticshttps://www.pharmaradar360.com/article/imported-malaria-in-the-uk-statistics-6d329ecef4fc16e6Pharma Surgeen2026-07-14T08:30:03.000ZImported malaria in the UK: statisticshttps://www.pharmaradar360.com/article/laboratory-confirmed-dengue-cases-statistics-8d90a3faa0277af2Pharma Surgeen2026-07-14T08:30:03.000ZLaboratory-confirmed dengue cases: statisticshttps://www.pharmaradar360.com/article/chikungunya-epidemiology-in-england-wales-and-northern-ireland-b54799970926b993Pharma Surgeen2026-07-14T08:30:03.000ZChikungunya: epidemiology in England, Wales and Northern Irelandhttps://www.pharmaradar360.com/article/astrazeneca-to-license-lung-cancer-drug-from-china-s-dizal-pharmaceutical-e00044dfaf25b2efPharma Surgeen2026-07-14T08:24:57.000ZAstraZeneca to license lung cancer drug from China's Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/regulator-eases-biosimilar-approval-requirements-waiving-some-phase-3-trial-data-74a4286650f7e089Pharma Surgeen2026-07-14T08:24:11.000ZRegulator eases biosimilar approval requirements, waiving some phase 3 trial datahttps://www.pharmaradar360.com/article/it-s-worth-another-try-campaign-from-terrence-higgins-trust-ddeb33985c6e33d1Pharma Surgeen2026-07-14T08:11:10.000ZIt’s Worth Another Try campaign from Terrence Higgins Trusthttps://www.pharmaradar360.com/article/elevara-medicines-appoints-biotech-veteran-as-ceo-cfc8e71c128d4ca4Pharma Surgeen2026-07-14T08:10:34.000ZElevara Medicines Appoints Biotech Veteran as CEOhttps://www.pharmaradar360.com/article/dizal-pharmaceutical-co-ltd-b04d647a4c9c9519Pharma Surgeen2026-07-14T08:09:31.000ZDizal Pharmaceutical Co Ltdhttps://www.pharmaradar360.com/article/a-study-identifies-a-relationship-between-cognitive-reserve-and-brain-structure-c3e9ead9ed0c4ef0Pharma Surgeen2026-07-14T08:00:00.000ZA study identifies a relationship between cognitive reserve and brain structure in young people at risk of psychosishttps://www.pharmaradar360.com/article/stocks-in-play-oncolytics-biotech-inc-fbe1074d8b2acddePharma Surgeen2026-07-14T07:51:00.000ZStocks in play: Oncolytics Biotech Inchttps://www.pharmaradar360.com/article/middle-east-pharmaceutical-grade-polyethylene-glycol-market-analysis-forecast-si-b5d6c3326357abacPharma Surgeen2026-07-14T07:48:57.000ZMiddle East Pharmaceutical Grade Polyethylene Glycol - Market Analysis, Forecast, Size, Trends and Insightshttps://www.pharmaradar360.com/article/ny-satsning-ska-starka-arbetet-mot-atstorningar-i-vastra-gotaland-c7cf5e72b9c38992Pharma Surgeen2026-07-14T07:48:41.000ZNy satsning ska stärka arbetet mot ätstörningar i Västra Götalandhttps://www.pharmaradar360.com/article/millions-of-unpaid-carers-to-get-recognition-and-earlier-support-dc45dda3a0797942Pharma Surgeen2026-07-14T07:45:00.000ZMillions of unpaid carers to get recognition and earlier supporthttps://www.pharmaradar360.com/article/celltrion-ends-keytruda-biosimilar-phase-3-trial-in-europe-early-77bcf35752cd71a6Pharma Surgeen2026-07-14T07:44:05.000ZCelltrion Ends Keytruda Biosimilar Phase 3 Trial in Europe Earlyhttps://www.pharmaradar360.com/article/zacks-industry-outlook-mckesson-cardinal-west-pharmaceutical-align-and-henry-b97b7e2e3854bec9Pharma Surgeen2026-07-14T07:31:00.000ZZacks Industry Outlook McKesson, Cardinal, West Pharmaceutical, Align and Henryhttps://www.pharmaradar360.com/article/laboratory-operations-and-technology-innovator-chris-clendening-joins-precision-470f37269fb622f5Pharma Surgeen2026-07-14T07:30:01.000ZLaboratory Operations and Technology Innovator Chris Clendening Joins Precision for Medicine to Lead Specialty Labshttps://www.pharmaradar360.com/article/astrazeneca-strikes-exclusive-licensing-deal-with-dizal-pharmaceutical-0a5c165d90f8da0cPharma Surgeen2026-07-14T07:20:10.000ZAstrazeneca strikes exclusive licensing deal with Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/okyo-pharma-moves-urcosimod-into-global-phase-3-trial-2bad6f7ff37c09d6Pharma Surgeen2026-07-14T07:19:02.000ZOKYO Pharma moves urcosimod into global phase 3 trialhttps://www.pharmaradar360.com/article/la-ema-recomienda-retirar-la-autorizacion-de-comercializacion-de-avacopan-tavneo-9690088523e2f7e1Pharma Surgeen2026-07-14T07:15:30.000ZLa EMA recomienda retirar la autorización de comercialización de avacopan (Tavneos)https://www.pharmaradar360.com/article/la-aemps-informa-de-las-nuevas-medidas-para-prevenir-el-dano-hepatico-con-avacop-389ff0fec745a2b4Pharma Surgeen2026-07-14T07:13:28.000ZLa AEMPS informa de las nuevas medidas para prevenir el daño hepático con avacopan (Tavneos)https://www.pharmaradar360.com/article/biovica-receives-ninth-work-order-from-a-leading-global-pharmaceutical-customer-873a444bfab5cf96Pharma Surgeen2026-07-14T07:10:00.000ZBiovica Receives Ninth Work Order From a Leading Global Pharmaceutical Customerhttps://www.pharmaradar360.com/article/delivering-life-how-resilience-and-innovation-define-the-future-of-pharmaceutica-90f5a58a9e4b8944Pharma Surgeen2026-07-14T07:02:53.000ZDelivering life: How resilience and innovation define the future of pharmaceutical logisticshttps://www.pharmaradar360.com/article/esg-transforming-the-pharmaceutical-supply-chain-4026dd6232429e44Pharma Surgeen2026-07-14T07:02:09.000ZESG: transforming the pharmaceutical supply chainhttps://www.pharmaradar360.com/article/nominations-open-for-unmc-s-highest-research-honors-03f587187911e746Pharma Surgeen2026-07-14T07:00:00.000ZNominations open for UNMC’s highest research honorshttps://www.pharmaradar360.com/article/cyclospora-the-tiny-parasite-behind-explosive-diarrhea-cases-bf9d6b78ae9e20f4Pharma Surgeen2026-07-14T07:00:00.000ZCyclospora: The tiny parasite behind “explosive diarrhea” caseshttps://www.pharmaradar360.com/article/what-does-resilience-show-about-healthy-aging-after-trauma-2df0ddba8c4eac18Pharma Surgeen2026-07-14T07:00:00.000ZWhat does resilience show about healthy aging after trauma?https://www.pharmaradar360.com/article/retirement-reception-july-28-for-shantaram-joshi-phd-96981807e96297cfPharma Surgeen2026-07-14T06:58:00.000ZRetirement reception July 28 for Shantaram Joshi, PhDhttps://www.pharmaradar360.com/article/college-of-public-health-inducts-new-delta-omega-members-3bb39a6c644afae0Pharma Surgeen2026-07-14T06:56:00.000ZCollege of Public Health inducts new Delta Omega membershttps://www.pharmaradar360.com/article/iluvien-meets-primary-endpoints-in-phase-4-uveitis-trial-at-six-months-adf6b2de1c203535Pharma Surgeen2026-07-14T06:54:16.000ZILUVIEN Meets Primary Endpoints in Phase 4 Uveitis Trial at Six Monthshttps://www.pharmaradar360.com/article/geospatial-approaches-for-mapping-zero-dose-prevalence-and-routine-childhood-imm-cb3df4e76aa8c9edPharma Surgeen2026-07-14T06:53:53.000ZGeospatial approaches for mapping zero-dose prevalence and routine childhood immunisation coverage in low- and lower-middle-income countries: A scoping reviewhttps://www.pharmaradar360.com/article/excellence-in-fluorinated-pharmaceutical-intermediates-baokai-pharma-sets-the-be-7af718492feee05aPharma Surgeen2026-07-14T06:48:03.000ZExcellence in Fluorinated Pharmaceutical Intermediates – Baokai Pharma Sets the Benchmark in High-End Fluorochemicals - ChemNethttps://www.pharmaradar360.com/article/bavarian-nordic-partner-applies-for-approval-of-chikungunya-vaccine-in-brazil-f3f58affdf89bd9fPharma Surgeen2026-07-14T06:20:23.000ZBavarian Nordic partner applies for approval of chikungunya vaccine in Brazilhttps://www.pharmaradar360.com/article/astrazeneca-to-license-lung-cancer-drug-from-china-s-dizal-pharmaceutical-7c8061545cdbdc9fPharma Surgeen2026-07-14T06:19:00.000ZAstraZeneca to license lung cancer drug from China's Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/south-korea-eases-biosimilar-rules-to-cut-trials-time-and-costs-chosunbiz-5b588d12e164a82fPharma Surgeen2026-07-14T06:18:00.000ZSouth Korea eases biosimilar rules to cut trials, time, and costs - CHOSUNBIZhttps://www.pharmaradar360.com/article/agenus-secures-340-million-to-fund-phase-3-robbin-trial-ab1f1902be3a1da3Pharma Surgeen2026-07-14T06:13:38.000ZAgenus Secures $340 Million to Fund Phase 3 ROBBIN Trialhttps://www.pharmaradar360.com/article/number-of-employees-of-nkgen-biotech-inc-otc-nkgnw-1b0c1a902cca9effPharma Surgeen2026-07-14T06:11:40.000ZNumber of employees of NKGen Biotech Inc. – OTC:NKGNWhttps://www.pharmaradar360.com/article/is-your-quality-system-built-for-2026-s-new-regulatory-reality-8079afceff5750acPharma Surgeen2026-07-14T06:04:30.000ZIs your quality system built for 2026’s new regulatory reality?https://www.pharmaradar360.com/article/the-fda-s-psychedelic-guidance-is-really-a-study-design-reckoning-20193ba8aa1c10abPharma Surgeen2026-07-14T05:54:16.000ZThe FDA’s Psychedelic Guidance Is Really a Study-Design Reckoninghttps://www.pharmaradar360.com/article/biosimilar-development-time-and-costs-to-be-reduced-phase-3-clinical-trial-requi-f14b65e8cda6a57cPharma Surgeen2026-07-14T05:33:58.000ZBiosimilar Development Time and Costs to Be Reduced... Phase 3 Clinical Trial Requirements Easedhttps://www.pharmaradar360.com/article/roche-introduces-cobas-hepatitis-d-virus-hdv-test-the-first-fully-automated-diag-6791ad35ce55c8a8Pharma Surgeen2026-07-14T05:00:00.000ZRoche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitishttps://www.pharmaradar360.com/article/price-to-sales-forward-of-cspc-hunan-jingfeng-pharmaceutical-co-ltd-class-a-szse-da54d8f1cdba552bPharma Surgeen2026-07-14T04:55:14.000ZPrice to sales forward of CSPC Hunan Jingfeng Pharmaceutical Co Ltd Class A – SZSE:000908https://www.pharmaradar360.com/article/biogen-shares-rise-5-ahead-of-alzheimer-s-drug-trial-data-a9e00bb1a32bb3abPharma Surgeen2026-07-14T04:34:15.000ZBiogen Shares Rise 5% Ahead of Alzheimer's Drug Trial Datahttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-could-be-21-below-fair-value-on-vitiligo-tri-cc8bc47eb5b6460dPharma Surgeen2026-07-14T04:31:00.000ZTeva Pharmaceutical Industries (TEVA) Could Be 21% Below Fair Value On Vitiligo Trial Progresshttps://www.pharmaradar360.com/article/scientists-discover-why-peach-fuzz-can-suddenly-make-you-itch-68f4c1581a8cdfa6Pharma Surgeen2026-07-14T04:16:23.000ZScientists discover why peach fuzz can suddenly make you itchhttps://www.pharmaradar360.com/article/pune-fda-seizes-unlicensed-ayurvedic-medicines-worth-50-36-lakh-f5eb137ba94323b7Pharma Surgeen2026-07-14T04:08:40.000ZPune FDA Seizes Unlicensed Ayurvedic Medicines Worth ₹50.36 Lakhhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-kangmei-pharmaceutical-co-ltd-class-a-sse-60-53b2fa81478b0e91Pharma Surgeen2026-07-14T03:41:28.000ZEnterprise value to EBIT forward of Kangmei Pharmaceutical Co., Ltd Class A – SSE:600518https://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-zhejiang-starry-pharmaceutical-co-ltd-cla-112fbbe4917a3440Pharma Surgeen2026-07-14T03:39:43.000ZEnterprise value to revenue forward of Zhejiang Starry Pharmaceutical Co., Ltd. Class A – SSE:603520https://www.pharmaradar360.com/article/veraxa-biotech-to-launch-ai-enabled-drug-discovery-collaboration-with-ardigen-to-ce4291ff1258bff4Pharma Surgeen2026-07-14T03:32:34.000ZVERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipelinehttps://www.pharmaradar360.com/article/peptron-chief-choi-buys-shares-signals-confidence-in-lilly-tie-up-and-tech-chosu-54dd5d5e4bf6e789Pharma Surgeen2026-07-14T03:20:00.000ZPeptron chief Choi buys shares, signals confidence in Lilly tie-up and tech - CHOSUNBIZhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-mycenax-biotech-inc-tpex-4726-62cd10bfb15f4dd1Pharma Surgeen2026-07-14T03:08:28.000ZEnterprise value to EBIT forward of Mycenax Biotech Inc. – TPEX:4726https://www.pharmaradar360.com/article/pharmaceutical-venture-announces-500m-expansion-in-northwest-austin-c995f0dab2ed0b3ePharma Surgeen2026-07-14T03:05:00.000ZPharmaceutical venture announces $500M expansion in Northwest Austinhttps://www.pharmaradar360.com/article/anzen-pmda-risk-communications-domperidone-oral-preparations-etc-posted-0081db583ce3911cPharma Surgeen2026-07-14T03:00:00.000Z[ANZEN]PMDA Risk Communications: Domperidone (oral preparations) etc. postedhttps://www.pharmaradar360.com/article/anzen-revisions-of-precautions-esomeprazole-magnesium-hydrate-etc-posted-33cdc31c2eb83d5bPharma Surgeen2026-07-14T03:00:00.000Z[ANZEN]Revisions of PRECAUTIONS: Esomeprazole Magnesium Hydrate, etc. postedhttps://www.pharmaradar360.com/article/biopharma-funds-surge-on-deals-and-drug-breakthroughs-eeb4b7fccc39b740Pharma Surgeen2026-07-14T02:57:47.000ZBiopharma Funds Surge on Deals and Drug Breakthroughshttps://www.pharmaradar360.com/article/large-block-sale-of-kubota-pharmaceutical-holdings-shares-8-19-4-32-by-evo-fund-e7fc5c5b832c362dPharma Surgeen2026-07-14T02:45:00.000ZLarge block sale of Kubota Pharmaceutical Holdings shares (8.19% → 4.32%) by Evo Fund and others.https://www.pharmaradar360.com/article/maharashtra-fda-crackdown-hits-dairy-and-gutkha-supply-chains-8b9bbf0bee203e06Pharma Surgeen2026-07-14T02:44:15.000ZMaharashtra FDA Crackdown Hits Dairy And Gutkha Supply Chainshttps://www.pharmaradar360.com/article/ireland-seeks-balance-on-biotech-incentives-and-patient-interests-c568aa6c4b563a31Pharma Surgeen2026-07-14T02:28:11.000ZIreland seeks balance on biotech incentives and patient interestshttps://www.pharmaradar360.com/article/australia-s-mesoblast-reaches-target-of-300-trial-patients-b08d6aedb1f7e8f5Pharma Surgeen2026-07-14T02:27:54.000ZAustralia's Mesoblast reaches target of 300 trial patientshttps://www.pharmaradar360.com/article/meet-the-ias-officer-leading-maharashtra-s-toughest-food-safety-crackdown-b2af99a3fe6a37b4Pharma Surgeen2026-07-14T02:13:49.000ZMeet the IAS officer leading Maharashtra's toughest food safety crackdownhttps://www.pharmaradar360.com/article/1-643-273d1d5fd0b6a2b9Pharma Surgeen2026-07-14T02:13:00.000Zがん遺伝子パネル検査による新たな治療選択が 予後改善を示唆 ―東北大学病院1,643例のリアルワールド解析―https://www.pharmaradar360.com/article/novo-nordisk-weaves-a-safety-net-hemophilia-drug-advances-as-glp-1-revenue-faces-26ad82d6654dfb45Pharma Surgeen2026-07-14T01:55:22.000ZNovo Nordisk Weaves a Safety Net: Hemophilia Drug Advances as GLP-1 Revenue Faces Halving in 2027https://www.pharmaradar360.com/article/astrazeneca-enters-exclusive-global-license-agreement-for-novel-oral-egfr-inhibi-4bd051a02d16cc16Pharma Surgeen2026-07-14T01:30:00.000ZAstraZeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceuticalhttps://www.pharmaradar360.com/article/yale-scientists-found-a-hidden-network-inside-the-eye-2a44b968bcf01001Pharma Surgeen2026-07-14T01:15:50.000ZYale scientists found a hidden network inside the eyehttps://www.pharmaradar360.com/article/exercise-doesn-t-just-strengthen-the-heart-it-rewires-it-7595b70e5cdf8991Pharma Surgeen2026-07-14T00:47:33.000ZExercise doesn't just strengthen the heart. It rewires ithttps://www.pharmaradar360.com/article/mesoblast-tests-one-injection-for-chronic-low-back-pain-7a9c6ef16455c3eaPharma Surgeen2026-07-14T00:37:14.000ZMesoblast Tests One Injection for Chronic Low Back Painhttps://www.pharmaradar360.com/article/mesoblast-achieves-target-of-300-treated-patients-in-pivotal-phase-3-trial-for-c-bc3a89fabcc77bcePharma Surgeen2026-07-14T00:35:00.000ZMesoblast Achieves Target of 300 Treated Patients in Pivotal Phase 3 Trial for Chronic Low Back Painhttps://www.pharmaradar360.com/article/after-sc-now-wearables-first-fda-approval-for-on-body-injectable-anticancer-drug-82311c8de21fab09Pharma Surgeen2026-07-14T00:32:54.000ZAfter SC, Now Wearables: First FDA Approval for On-Body Injectable Anticancer Drug in the UShttps://www.pharmaradar360.com/article/astrazeneca-filed-form-6-k-6d9a96fbef59ff7fPharma Surgeen2026-07-14T00:00:00.000ZAstraZeneca filed Form 6-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-0ba56c2a20116428Pharma Surgeen2026-07-14T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/local-sensory-innervation-shapes-anti-tumor-immunity-in-lung-cancer-e6f9cf01644c461aPharma Surgeen2026-07-14T00:00:00.000ZLocal sensory innervation shapes anti-tumor immunity in lung cancerhttps://www.pharmaradar360.com/article/a-framework-for-comparative-analysis-of-human-and-mouse-cortical-neuron-dendrite-7f7eee2b1bb3a372Pharma Surgeen2026-07-14T00:00:00.000ZA framework for comparative analysis of human and mouse cortical neuron dendrites in corresponding brain regionshttps://www.pharmaradar360.com/article/oxytocin-promotes-socially-triggered-cataplexy-ee0f2b457d5b6cd2Pharma Surgeen2026-07-14T00:00:00.000ZOxytocin promotes socially triggered cataplexyhttps://www.pharmaradar360.com/article/mhra-s-radical-rare-disease-proposal-6b55a78c4ff1435fPharma Surgeen2026-07-14T00:00:00.000ZMHRA’s radical rare disease proposalhttps://www.pharmaradar360.com/article/first-car-t-for-solid-tumors-326415110516e522Pharma Surgeen2026-07-14T00:00:00.000ZFirst CAR T for solid tumorshttps://www.pharmaradar360.com/article/sangamo-exits-stage-f64c46174d54e453Pharma Surgeen2026-07-14T00:00:00.000ZSangamo exits stagehttps://www.pharmaradar360.com/article/an-rna-guided-chromatin-shredder-for-selective-cell-killing-d5c1c178da3600c9Pharma Surgeen2026-07-14T00:00:00.000ZAn RNA-guided ‘chromatin shredder’ for selective cell killinghttps://www.pharmaradar360.com/article/form-follows-function-for-rna-editing-c69215dc147dab33Pharma Surgeen2026-07-14T00:00:00.000ZForm follows function for RNA editinghttps://www.pharmaradar360.com/article/integrating-chromatin-architecture-and-functional-analysis-fb79ea237e262387Pharma Surgeen2026-07-14T00:00:00.000ZIntegrating chromatin architecture and functional analysishttps://www.pharmaradar360.com/article/biotech-news-from-around-the-world-452a263224d91085Pharma Surgeen2026-07-14T00:00:00.000ZBiotech news from around the worldhttps://www.pharmaradar360.com/article/bispecific-antibodies-3d866b23ff80567ePharma Surgeen2026-07-14T00:00:00.000ZBispecific antibodieshttps://www.pharmaradar360.com/article/academia-should-recognize-community-partnerships-as-having-societal-impact-650544ff010281f0Pharma Surgeen2026-07-14T00:00:00.000ZAcademia should recognize community partnerships as having societal impacthttps://www.pharmaradar360.com/article/the-enhanced-games-and-the-normalization-of-doping-a-public-health-concern-68fb7aa09cb29766Pharma Surgeen2026-07-14T00:00:00.000ZThe Enhanced Games and the normalization of doping: a public health concernhttps://www.pharmaradar360.com/article/bird-flu-h5n1-in-australia-protect-australian-species-from-bird-flu-virus-030042679a3692bdPharma Surgeen2026-07-14T00:00:00.000ZBird flu H5N1 in Australia: protect Australian species from bird flu virushttps://www.pharmaradar360.com/article/ai-models-one-country-s-fears-become-everyone-s-constraint-e9791dbb857372daPharma Surgeen2026-07-14T00:00:00.000ZAI models: one country’s fears become everyone’s constrainthttps://www.pharmaradar360.com/article/mathematics-formula-found-on-maya-wall-rivals-insights-of-ancient-masters-1673cb355d21e5f4Pharma Surgeen2026-07-14T00:00:00.000ZMathematics formula found on Maya wall rivals insights of ancient mastershttps://www.pharmaradar360.com/article/climate-free-fall-why-the-biggest-risk-to-our-economies-is-yet-to-be-recognized-b8ed0f4bf7be20aaPharma Surgeen2026-07-14T00:00:00.000Z‘Climate free fall’: why the biggest risk to our economies is yet to be recognizedhttps://www.pharmaradar360.com/article/could-this-mysterious-disappearing-organ-hold-the-key-to-longevity-894c36e03c965976Pharma Surgeen2026-07-14T00:00:00.000ZCould this mysterious disappearing organ hold the key to longevity?https://www.pharmaradar360.com/article/africa-s-response-to-this-ebola-outbreak-shows-how-to-shape-global-health-d58a2603670e4d12Pharma Surgeen2026-07-14T00:00:00.000ZAfrica’s response to this Ebola outbreak shows how to shape global healthhttps://www.pharmaradar360.com/article/dna-shredding-crispr-enzyme-takes-aim-at-cancer-cells-4964e5766eb56c29Pharma Surgeen2026-07-14T00:00:00.000ZDNA-shredding CRISPR enzyme takes aim at cancer cellshttps://www.pharmaradar360.com/article/how-the-calendar-came-to-be-5fc66811b4794688Pharma Surgeen2026-07-14T00:00:00.000ZHow the calendar came to behttps://www.pharmaradar360.com/article/the-race-to-explore-the-deep-ocean-four-technologies-transforming-research-66d6891ee8d54270Pharma Surgeen2026-07-14T00:00:00.000ZThe race to explore the deep ocean: four technologies transforming researchhttps://www.pharmaradar360.com/article/seeking-an-industry-role-after-your-phd-make-sure-your-cv-reflects-that-561963a5fb9dc8baPharma Surgeen2026-07-14T00:00:00.000ZSeeking an industry role after your PhD? Make sure your CV reflects thathttps://www.pharmaradar360.com/article/my-research-on-mice-is-causing-me-stress-how-can-i-become-more-resilient-291b85064a62a0d4Pharma Surgeen2026-07-14T00:00:00.000ZMy research on mice is causing me stress. How can I become more resilient?https://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c272df6abcd101baPharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-7998e052e6da1813Pharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-ed05cea0d20bb7e9Pharma Surgeen2026-07-14T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-009aca5d301e76daPharma Surgeen2026-07-14T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-ef92a6bc782cc6f1Pharma Surgeen2026-07-14T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-9ae7520221afcd9fPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-1e9899ba523c063bPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-46288a9dd45bd33aPharma Surgeen2026-07-14T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-a8ddf1274a1143acPharma Surgeen2026-07-14T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-b494dfb2531a641aPharma Surgeen2026-07-14T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-fa6ad3fae62a3830Pharma Surgeen2026-07-14T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-7202823f5613640ePharma Surgeen2026-07-14T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-c3926f634be61873Pharma Surgeen2026-07-14T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-a177c56b0509a86ePharma Surgeen2026-07-14T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/psychedelic-drugs-considerations-for-clinical-investigations-guidance-for-indust-38698db823b8aa3ePharma Surgeen2026-07-14T00:00:00.000ZPsychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-8bdd457f2ecdf21dPharma Surgeen2026-07-14T00:00:00.000ZConsiderations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Commentshttps://www.pharmaradar360.com/article/request-for-information-training-and-care-delivery-models-for-safe-administratio-c469aff76275a755Pharma Surgeen2026-07-14T00:00:00.000ZRequest for Information, Training and Care Delivery Models for Safe Administration of Potential FDA-Approved Psychedelic Therapies in Ambulatory Clinical Settingshttps://www.pharmaradar360.com/article/shane-lydon-m-d-decision-and-order-e3c4f39d8d50815ePharma Surgeen2026-07-14T00:00:00.000ZShane Lydon, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/barlow-st-clair-lynch-m-d-decision-and-order-335d365c1fe90bc5Pharma Surgeen2026-07-14T00:00:00.000ZBarlow St-Clair Lynch, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/david-enright-m-d-decision-and-order-9e1ba6f3451be035Pharma Surgeen2026-07-14T00:00:00.000ZDavid Enright, M.D.; Decision and Orderhttps://www.pharmaradar360.com/article/government-owned-inventions-availability-for-licensing-0762c7c858438582Pharma Surgeen2026-07-14T00:00:00.000ZGovernment-Owned Inventions; Availability for Licensinghttps://www.pharmaradar360.com/article/designated-placement-requirements-under-titles-iv-e-and-iv-b-for-lgbtqi-children-f598399f09c5a965Pharma Surgeen2026-07-14T00:00:00.000ZDesignated Placement Requirements Under Titles IV-E and IV-B for LGBTQI+ Children; Rescissionhttps://www.pharmaradar360.com/article/formal-meetings-between-fda-and-sponsors-or-requestors-of-over-the-counter-monog-2da188edbaea0bf5Pharma Surgeen2026-07-14T00:00:00.000ZFormal Meetings Between FDA and Sponsors or Requestors of Over-the-Counter Monograph Drugshttps://www.pharmaradar360.com/article/topical-dermatologic-corticosteroids-in-vivo-bioequivalence-guidance-for-industr-2e7d05a656365093Pharma Surgeen2026-07-14T00:00:00.000ZTopical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availabilityhttps://www.pharmaradar360.com/article/national-vaccine-injury-compensation-program-list-of-petitions-received-772f73b828f20d6cPharma Surgeen2026-07-14T00:00:00.000ZNational Vaccine Injury Compensation Program; List of Petitions Receivedhttps://www.pharmaradar360.com/article/federal-register-notice-change-in-eligibility-period-for-refugee-cash-assistance-133526f517e8c6d6Pharma Surgeen2026-07-14T00:00:00.000ZFederal Register Notice: Change in Eligibility Period for Refugee Cash Assistance and Refugee Medical Assistancehttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-omb-review-comment-reque-ab650734991ce728Pharma Surgeen2026-07-14T00:00:00.000ZAgency Information Collection Activities: Submission for OMB Review; Comment Requesthttps://www.pharmaradar360.com/article/spadbarnskollaps-ovanligt-men-kan-fa-allvarliga-konsekvenser-cdedad4bf5d629f5Pharma Surgeen2026-07-14T00:00:00.000ZSpädbarnskollaps ovanligt men kan få allvarliga konsekvenserhttps://www.pharmaradar360.com/article/metaboliskt-syndrom-kopplat-till-snabbare-aldrande-av-hjarnan-3757c447357617b8Pharma Surgeen2026-07-14T00:00:00.000ZMetaboliskt syndrom kopplat till snabbare åldrande av hjärnanhttps://www.pharmaradar360.com/article/centrum-for-halsokriser-deltar-i-eu-mote-om-europas-beredskap-for-nasta-halsokri-8d179752b6172618Pharma Surgeen2026-07-14T00:00:00.000ZCentrum för hälsokriser deltar i EU-möte om Europas beredskap för nästa hälsokrishttps://www.pharmaradar360.com/article/jama-d16359f9906962fbPharma Surgeen2026-07-14T00:00:00.000ZJAMAhttps://www.pharmaradar360.com/article/audio-highlights-june-18-2026-51153ab717a54f62Pharma Surgeen2026-07-14T00:00:00.000ZAudio Highlights June 18, 2026https://www.pharmaradar360.com/article/acog-releases-maternal-immunization-schedule-breaking-from-cdc-82fc7577321bd84aPharma Surgeen2026-07-14T00:00:00.000ZACOG Releases Maternal Immunization Schedule, Breaking From CDChttps://www.pharmaradar360.com/article/postoperative-delirium-may-predict-long-term-cognitive-decline-ffff2951adb09295Pharma Surgeen2026-07-14T00:00:00.000ZPostoperative Delirium May Predict Long-Term Cognitive Declinehttps://www.pharmaradar360.com/article/about-1-in-5-us-youth-use-ai-chatbots-for-mental-health-advice-fb35df61112da7cePharma Surgeen2026-07-14T00:00:00.000ZAbout 1 in 5 US Youth Use AI Chatbots for Mental Health Advicehttps://www.pharmaradar360.com/article/fda-advises-against-over-the-counter-skin-lightening-products-4ca8fc84e14f972aPharma Surgeen2026-07-14T00:00:00.000ZFDA Advises Against Over-the-Counter Skin Lightening Productshttps://www.pharmaradar360.com/article/ultraprocessed-foods-linked-to-cardiometabolic-risks-998823d8d34df1caPharma Surgeen2026-07-14T00:00:00.000ZUltraprocessed Foods Linked to Cardiometabolic Riskshttps://www.pharmaradar360.com/article/acp-ama-decry-executive-order-to-change-childhood-vaccine-schedule-9d4258571df8e2c4Pharma Surgeen2026-07-14T00:00:00.000ZACP, AMA Decry Executive Order to Change Childhood Vaccine Schedulehttps://www.pharmaradar360.com/article/new-glp-1-drug-data-presented-at-ada-2026-8884af70a49556d1Pharma Surgeen2026-07-14T00:00:00.000ZNew GLP-1 Drug Data Presented at ADA 2026https://www.pharmaradar360.com/article/in-the-glp-1-drug-era-physical-activity-still-matters-heart-group-says-df38a435297b388cPharma Surgeen2026-07-14T00:00:00.000ZIn the GLP-1 Drug Era, Physical Activity Still Matters, Heart Group Sayshttps://www.pharmaradar360.com/article/stopping-alzheimer-disease-b8aea2cb9c134c6ePharma Surgeen2026-07-14T00:00:00.000ZStopping Alzheimer Diseasehttps://www.pharmaradar360.com/article/low-back-pain-a-review-41179adadb3c6e19Pharma Surgeen2026-07-14T00:00:00.000ZLow Back Pain: A Reviewhttps://www.pharmaradar360.com/article/audio-highlights-june-12-2026-5cf18f18b31f78a0Pharma Surgeen2026-07-14T00:00:00.000ZAudio Highlights June 12, 2026https://www.pharmaradar360.com/article/nursing-home-closures-and-access-to-long-term-care-a49b3c42ee0fdb26Pharma Surgeen2026-07-14T00:00:00.000ZNursing Home Closures and Access to Long-Term Care